IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women

Window studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tumor cell positivity for the proliferation marker Ki67 is often used as a proxy for treatment response. Immunohistochemistry (IHC)-based Ki67 on tissue from neo-adjuvant trials was previously reported t...

Descripción completa

Detalles Bibliográficos
Autores principales: Joosten, Stacey E. P., Wellenstein, Marius, Koornstra, Rutger, van Rossum, Annelot, Sanders, Joyce, van der Noort, Vincent, Ferrandez, Maria C., Harkes, Rolf, Mandjes, Ingrid A. M., Rosing, Hilde, Huitema, Alwin, Beijnen, Jos H., Wesseling, Jelle, van Diest, Paul J., Horlings, Hugo M., Linn, Sabine C., Zwart, Wilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528844/
https://www.ncbi.nlm.nih.gov/pubmed/34671036
http://dx.doi.org/10.1038/s41523-021-00344-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528844/
https://www.ncbi.nlm.nih.gov/pubmed/34671036
http://dx.doi.org/10.1038/s41523-021-00344-3

Ejemplares similares